Loading stock data…
Palisade Bio (PALI)
$2.23+0.34 (+17.99%)
After Hours$2.23+0.00 (+0.00%)· Last close Jun 29
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Palisade Bio, Inc. in the Healthcare sector is trading at $2.23 with a market capitalization of $291M. Wall Street consensus targets $10.50 (8 analysts), implying a +370.9% move over the next 12 months. The stock is currently 22% below its 52-week high of $2.86, remaining 22.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +370.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.75M↓ | -$9.98M↓ | -$2.92M↓ | -$2.84M↓ | -$2.31M |
| Net Income | -$9.60M↓ | -$8.90M↓ | -$2.87M↓ | -$2.78M↓ | -$2.23M |
Peer Comparison
JNJUNHPFE
Fundamentals
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$291.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.96%
Volume
Today's trading volume
10.78M
Recent News
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M
Palisade Bio Inc. (NASDAQ:PALI) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, Palisade reported Q1 2026 earnings, recording a net increase in operating expenses to fund its clinical pipeline. R&D expenses rose to $6.4 million for the quarter, compared to $1.0 million in Q1 2025, driven by […]
We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Palisade Bio ( NASDAQ:PALI...